! Bouncers, Bottom Pinchers, and Knife-Catchers Anonymous !

[flippa]

MGNT REVERSAL STARTING AFTER ALL TIME LOW! EASY 3 BAGGER!

[ih8aloss]

~~~~$QTMM ~~~~ Put this on your radar, it will be Quite The Money Maker. Below is their latest PR to get you going on your DD, https://globenewswire.com/news-release/2017/01/04/903144/0/en/Quantum-Materials-Corp-to-Present-Heavy-Metal-Free-Quantum-Dot-Display-Film-at-2017-Consumer-Electronics-Show.html

Quantum Materials Corp to Present Heavy Metal-Free Quantum Dot Display Film at 2017 Consumer Electronics Show

January 04, 2017 07:00 ET | Source: Quantum Materials Corp
photo-release

Quantum Materials Corp Heavy Metal Free Display Film (Top) as compared with leading display manufacturer film (Below) (*** NOT part of PR - The only leading display manufacturer currently on the market is Samsung, draw your own conclusion.)

50 Watt LED Power Supply Driving Quantum Materials Heavy Metal-Free Quantum Dot Display Thin Film on top of frame as compared to Major Manufacturer QD Display Film on bottom, both through polarizing filter

Quantum Materials

SAN MARCOS, Texas, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Quantum Materials Corp (OTCBB:QTMM) today announced that the Company will be presenting its heavy metal-free quantum dot film by appointment to television, monitor and mobile display manufacturers at the 2017 Consumer Electronics Show in Las Vegas this week.

“We are excited to present our QD display film to leading display manufacturers at CES seeking to incorporate advanced quantum dot technology into their TV, monitor and mobile device offerings,” said Quantum Materials CEO and Chairman Stephen B. Squires. “Our heavy metal-free display film affords display designers the ability to create brighter and more vivid wider color-gamut devices, while fulfilling environmental mandates to restrict the use of heavy metals in consumer and professional electronics.”

“Due to relatively high cost, implementation of quantum dot display film has been heavily weighted to the high-end display market. We believe Quantum Materials Corp’s low-cost high-volume quantum dot manufacturing approach will enable the enhanced viewing experience made possible with quantum dots to be enjoyed by consumers along a much broader range of price points,” said Toshi Ando, Quantum Materials Corp Senior Director of Business Development.

Interested display manufacturers can schedule a demo appointment by contacting Toshi Ando, Quantum Materials Corp Senior Director of Business Development, at [e-mail] or 510.300.4021.

ABOUT QUANTUM MATERIALS CORP.
Quantum Materials Corporation (QMC) develops and manufactures quantum dots and nanomaterials for use in medical, display, solar energy and lighting applications through its patented volume production process. QMC's volume manufacturing methods enable consistent quality and scalable cost reductions to drive innovative discovery to commercial success. The company’s technology continues to move the future of quantum dots to the present. QMC’s products are the foundation for technologically superior, energy efficient and environmentally sound LCD UHD displays, the next generation of solid-state lighting, solar photovoltaic power applications and advanced battery and energy storage solutions. Wholly-owned subsidiary Solterra Renewable Technologies develops sustainable quantum dot solar technology. For more information follow Quantum Materials Corp at www.QMCDOTS.com and on LinkedIn and Twitter.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report and in reports subsequently filed by us with the Securities and Exchange Commission ("SEC" . All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at http://www.sec.gov/ or from our website. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.

For more information please contact:

BUSINESS INQUIRIES:

Toshi Ando
Sr. Director of Business Development for Asia/Pacific
510.300.4021


MEDIA:

Rich Schineller
941.780.8100


INVESTOR RELATIONS:

Clay Chase
858.456.7300

http://www.QMCDots.com

QTMM Chart

[Princetonstockclub]

SSH…nine days RED find worst stock ever!!!!! sold out done worst of 2017

[Princetonstockclub]

SSH…nine days RED find worst stock ever!!!!! sold out done worst of 2017

[Angel010910]

$ACNV .007 UPTRENDING ON NO BUZZZZZZZZZZZZZZ WAS ALMOST 40 CENTS RECENTLY. ACNV 7 MILLION FLOAT AND TINY 100 MILLION A/S Cant believe ACNV is so hard to figure to 99.999999% pennystock traders out there. Too funny. Breaking .015 tomorrow.

[EpicPlays]

CGRA

[Pennybuster]

$APHB .50 Beaten Down Smallcap BioTech..Video

[BottomBounce]

$GEVO Stock Concentration on Shares of Gevo, Inc. (NASDAQ:GEVO)
http://libertynewsrecord.com/stock-concentration-on-shares-of-gevo-inc-nasdaqgevo/25533/

[Pennybuster]

$APHB .62 http://www.buff.ly/2fuNm8Y

[Pennybuster]

$CGIX In at 1.60 Zacks Investment Research upgraded shares of Cancer Genetics Inc. (NASDAQ:CGIX) from a hold rating to a buy rating in a report issued on Tuesday. Zacks Investment Research currently has $1.75 price target on the stock.
According to Zacks, “Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company’s tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. “
Other equities research analysts have also issued reports about the stock. Rodman & Renshaw assumed coverage on shares of Cancer Genetics in a research note on Monday, September 26th. They set a buy rating and a $6.00 target price on the stock. HC Wainwright assumed coverage on shares of Cancer Genetics in a research note on Tuesday, September 27th. They set a buy rating and a $6.00 target price on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Cancer Genetics currently has a consensus rating of Buy and a consensus target price of $7.19.


Cancer Genetics (NASDAQ:CGIX) remained flat at $1.60 on Tuesday. The stock had a trading volume of 51,145 shares. The firm’s market cap is $25.79 million. Cancer Genetics has a 1-year low of $1.10 and a 1-year high of $3.82. The firm has a 50-day moving average of $1.56 and a 200-day moving average of $1.96.
Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. Cancer Genetics had a negative net margin of 74.07% and a negative return on equity of 63.26%. The company had revenue of $6.80 million for the quarter, compared to analyst estimates of $6.93 million. During the same period in the prior year, the company earned ($0.56) earnings per share. The firm’s revenue was up 70.0% on a year-over-year basis. Equities analysts forecast that Cancer Genetics will post ($1.17) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fairbanks Capital Management Inc. increased its position in Cancer Genetics by 0.9% in the third quarter. Fairbanks Capital Management Inc. now owns 235,170 shares of the company’s stock valued at $411,000 after buying an additional 2,000 shares during the period. Vanguard Group Inc. increased its stake in Cancer Genetics by 3.3% in the second quarter. Vanguard Group Inc. now owns 326,966 shares of the company’s stock worth $651,000 after buying an additional 10,328 shares during the last quarter. Eagle Global Advisors LLC increased its stake in Cancer Genetics by 69.3% in the second quarter. Eagle Global Advisors LLC now owns 84,320 shares of the company’s stock worth $168,000 after buying an additional 34,510 shares during the last quarter. Bridger Management LLC acquired a new stake in Cancer Genetics during the first quarter worth approximately $149,000. Finally, Sabby Management LLC increased its stake in Cancer Genetics by 145.5% in the second quarter. Sabby Management LLC now owns 199,580 shares of the company’s stock worth $397,000 after buying an additional 118,280 shares during the last quarter. Hedge funds and other institutional investors own 11.08% of the company’s stock.
Cancer Genetics Company Profile
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
5 Day Chart for NASDAQ:CGIX

[MrSaintor]

TNDM Bounce ! off its 52wk low - good news about there insulin pumps !

[roofingisawesome]

NWPN bounce alert for this MJ low floater

[MaxPowerLove$Ihub]

$CHRO: Out on the Fringes & Creativity

There’s an early chapter in one of my favorite books, ‘Lovemarks’ by Kevin Roberts, which talks about the concept of “the fringes” and “the power of the edge”. Author, Kevin Roberts explains how great ideas typically start on the fringes or the edge as opposed to the safe and conventional center. It seems to me that oftentimes, great ideas do come to us; however, we then rationalize them down into mediocre ideas in our attempt to be good businessmen.

This downward process starts with not wanting to be offensive, or with wanting to appease the safe zone or “cheap seats”. Nowadays, a great idea even has to go through the politically-correct distortion-vortex as well – which in my humble opinion, if not done correctly, can rob the entire soul of the idea. My point here is that it takes a process, great minds and complete present-ness or self-awareness to bring great ideas into fruition.

I believe that our idea and vision for a 21st century utility company is certainly cutting edge for the following reasons: a) we are going to bring smart home/automation to the masses, b) we are converging that offering with a responsible energy offering, and c) we are making it affordable. This, of course, is only the beginning. Sure I am biased and we all think our baby is the cutest… still, my point here is that this massive undertaking will require intelligent, effective and innovative branding and messaging.

As many of you already know, we’re now engaged with New York-based Creative Ad-Agency, HQ Creative (see press release here); but what people do not know is that our wholly owned subsidiary, Chron Home Services, will be undergoing a brand and name change. This change is part of our engagement with the experts at HQ Creative. I believe that we have come up with a name and brand that is most definitely from the fringes – it is brilliant, yet edgy, and it encompasses the entire soul and lifestyle that our home services products and our company represent. This new name and brand will be officially revealed when we debut our e-commerce website, which of course, is our official national company launch as well.

In any event, this past week I reviewed the very first rough cuts on the video production work and other materials being developed by our creative team and candidly, they have captured the soul of what we stand for and more importantly, for where we are going to be 5 years from now. It is truly exciting and I cannot wait to share it with the public when we go live. As always, we appreciate your feedback. The Founder and Chief Plot-Stirrer at HQ Creative, Mr. Mitchell Stuart, absolutely captured our vision… and more importantly, he was sold on it. This picture here is myself and Mitchel – yeah, we look like we’re putting the band back together again.

Okay, for clarity’s sake and to avoid confusion – what does this name/brand change actually mean? First of all, this is only pertinent to our home services company. For those of you who do not understand our corporate structure, please take the time to read a blog post I did a few weeks back on our corporate structure (click here). Secondly, this change has nothing to do with our parent company – our core infrastructure will remain the same. This means there will be no change to our ticker or to the parent company name, which is ‘The Chron Organization, Inc.’ The change is purely for our wholly owned home services company and our branding efforts to help us go out there and capture a million customers.

Anyway, I hope and trust that you will be as excited as we are about this upcoming product/site/brand launch… we plan on taking over this space in a ballooning industry and becoming the thought leader!!

Yours Truly,

Alex Rodriguez,

Steward of the CHRON Vision



http://www.chronorganization.com/chron/out-on-the-fringes-creativity/

- Go CHRO

[mary777]

KALY making a move. 6.7 million float, moves on air. Great things happening!

[MaxPowerLove$Ihub]

$COBI: Chart says reversal starting.

[MaxPowerLove$Ihub]

$CHRO, $DCLT, $SURE: accumulation continues

[mary777]

KALY at bottom. 6.7 million in float. About to explode, major news rumored.

[MaxPowerLove$Ihub]

$IDGC, $VGID, $SURE, $COBI, $GNPT,
$LUSI, $MEDT, $SDVI: $.000x with great potential

[janitor_unbound]

__INVU -56% Friday back to .005

[Pennybuster]

$IFAN .0006 Chart. Take a Look At The 50 and 200 Day Moving Average.



Potential Bounce Play Here.










Historical Trading Link: http://ih.advfn.com/stock-market/USOTC/ifan-financial-inc-IFAN/historical




http://www.otcmarkets.com/stock/IFAN/profile
Website.. Filings.. Company Info..

[roofingisawesome]

CCTC bouncing high on NO VOLUME yet!
Clean Coal Technologies...no industry more hated!

[TRAPPER JIM]

LBRG 23.4 mil float bounce coming http://www.stockscores.com/quickreport.asp?ticker=lbrg&x=11&y=9

[MaxPowerLove$Ihub]

***** $CHRO: bids continue to grow, ask thinning out, Super Stong uptrend pattern~ No dilution~ Bullish! *****

[MaxPowerLove$Ihub]

$DCLT: chart shows tight channel, breakout coming

[MaxPowerLove$Ihub]

$MEDT, $SDVI, $SWHI, $SFOR, $COBI, $SURE, $MTVX, $LUSI, $GNPT, $VGID, $IDGC, $: $.0001-.0015 bounce play on hard dip here!

[realwill]

BETS, Multiple Must Reads Listed Below: Expected big breakout soon!

HUNTINGTON, NY--(Marketwired - Aug 31, 2016) - SeanieMac International ( OTC PINK : BETS ) today announced a strategic partnership with Dev Clever, the award winning digital innovation and marketing agency behind global household brands such as Nescafé, Pepsi, Honda and Bentley. Providing our clients with truly innovative digital platforms and consumer engagement applications that not only make their customers standout, but also get noticed. Over the past few years, Dev Clever has impacted the E-Gaming sector and produced leading marketing platforms for European leaders such as William Hill, Bet Victor and Corals to name a few. Providing real consumer engagement that stems from innovation and ultimately leads to higher levels of player conversions, Dev Clever has carved a name for themselves in this highly competitive market as digital leaders.

Managing Director of Dev Clever, Chris Jeffries said, "Both myself and the team at Dev Clever are more than excited about working in partnership with SeanieMac on reintroducing this terrific brand in to the sector, not only in Ireland and the UK but also throughout Europe. We feel the forwarded management team coupled with our sector leading innovative approach is the perfect recipe for success and we are confident that Seanie Mac together with Dev Clever will establish a brand that is the benchmark for consumer experience in the e-gaming space."

SeanieMac International Ltd (OTCMKTS:BETS) has set September 16, as the launch date for its new online sports-book and casino platform. The company stated that everything was going according to plan and it was on target to meet the mid-September deadline. In addition to this, BETS has also been busy maintaining its strong relationships, with the British Jockey Club. The company is scheduled to sponsor approximately five race meetings, across the UK, in August.

The COO of BETS, Garreth Core, expressed his delight at the announcement and stated that the company had been working hard with Optima, to meet its goals. He also revealed that the website would also host a number of features, to enhance user experience. Mr. Core went on to conclude that the company would be announcing new partnerships for the platform, very soon.

It should be noted here that work on the platform had only recently begun, when the company engaged Optima for the setup of the multichannel gaming suite platform, on July 26. The engagement includes mobile and web products at the forefront and a MarginMaker 2 system. Initially it had been announced that trading would commence in August.

The first of the series of meetings in UK was held on August 4, at Haydock Park. The meeting has been sponsored by the Apollo Bet brand of the company. Leon Hosking, the head of sports-book and trading for the brand, stated that these meetings were vital to SeanieMac’s brand awareness. He went on to point out that this was done through televised coverage of these meetings, across racing channels. Mr. Hosking claimed that this was part of the company’s strategy for the year. He revealed that higher gross profits would mean paying down of the credit facility of BETS and retiring of the company’s convertible debt.

LONDON, UNITED KINGDOM -- (Marketwired) -- 07/26/16 -- SeanieMac International, Ltd. (OTC PINK: BETS), the UK & Ireland online sports betting and e-gaming operator, has reached an agreement with software development firm OPTIMA for the setup of a new Multichannel Gaming Suite Platform. This deal includes Margin Maker 2 system and the establishment of new web, mobile front end products. Trading is targeted to begin in August.

Shane O'Driscoll, CEO, SeanieMac, said: "The significance of moving from a white-label led operation to licensing our own software is a massive leap forward in our business development and growth strategy. Having our own software licensed from an industry leader allows us to have full control over our own destiny. This now places us firmly in the 'driver's seat' and further accelerates our plans of becoming a premier online bookmaker and industry leader. This sizeable investment in our business infrastructure underscores our commitment for future growth."

Garreth Core, COO, SeanieMac, stated: "We are delighted to announce our new partnership with one of the world's leading sports betting and gaming platform software suppliers, OPTIMA. This is a major corporate development for our business and highlights our strategy to become an industry leader. For SeanieMac, the agreement allows us full flexibility over our business and enables us to offer our customers more value, more opportunities, a superb desktop and mobile user experience."

Jacob Curciel, CEO and founder of Optima, concluded: "We are very excited to have the opportunity to work with SeanieMac for the development of a dedicated full OPTIMA sports betting and e-gaming multichannel suite. Passion and know-how for the sports betting and gaming business is a must-have to be a market leader. SeanieMac's team has demonstrated they score very high on these values.

"At Optima, through the delivery of a turn-key platform, we will ensure our partner has the technology and products to achieve their objective of leading the market while delivering the best and most enjoyable customer experience across all channels."

HUNTINGTON, NY -- (Marketwired) -- 07/20/16 -- SeanieMac International, Ltd. (OTC PINK: BETS)

As part of the 2016 strategy to move to better financing terms, SeanieMac International announced that after a several week screening process that began on April 7th they had accepted a term sheet for a $7.5 million in revolving credit.

500k of this facility will be made available and drawn down right away and the balance is based on a ratio of the Company's revenues. The term sheet proposed provides that secured line is repaid with 20% of the Company's monthly revenues until retired. Closing on the facility is subject to final due diligence, legal documentation, and normal closing conditions.

SeanieMac President Shane O'Driscoll stated, "We are hoping to close the transaction by mid August to coincide with the targeted launch date of our new platform.

"The size of the line is in place to support further acquisitions if needed. We will continue to seek to improve our cost of capital as the Company continues to hit milestones. The ability to replace 100% equity lines with debt that can be repaid through revenues reflects the next step in the company's evolution."

HUNTINGTON, NY -- (Marketwired) -- 07/06/16 -- SeanieMac International Ltd. (OTC PINK: BETS) announced today, that after an impressive May with booked revenue in excess of $1.2 million, SeanieMac continues to see record results in its sportsbook and casino revenues (turnover) for the month ended June 30, 2016.

Total Revenue for June 2016 was $5,045,000, an increase of over 300% from the prior month. Preliminary 2nd Quarter revenues were $7,370,000 versus $2,656,000 for the 1st Quarter 2016. This reflects an increase of over 270% in Quarter over Quarter revenues.

Gross profit for June 2016 was approximately $200,000.

SeanieMac CEO Shane O'Driscoll stated, "We continue to make outstanding progress with our sportsbook and casino properties. We are driving the business forward and look forward to our upcoming launch."

HUNTINGTON, NY -- (Marketwired) -- 05/11/16 -- SeanieMac UK (OTC PINK: BETS) announces over $3.2 million in sports bets revenue taken in its newly combined Sportsbook operation. These considerable results do not include casino games or reflect the higher margins the company anticipates with the launch of its advanced new platform this summer.

In addition, we were pleased to welcome over 8300 new registered customers on the site since the combined operations began. The 1600% increase in new members reflects the company's substantial investment in targeted marketing and promotion geared toward building a greater and more substantial customer base. The budget utilized of over 500k in the first quarter on bet promotions, sponsorships, specials and direct marketing has been proving to be a great success.

HUNTINGTON, NY -- (Marketwired) -- 04/27/16 -- SeanieMac International Ltd (OTC PINK: BETS) --

Dear Shareholders,

I'd like to thank all of our loyal shareholders for your steadfast support and incredibly adroit ability in keeping abreast of company activities, our competitors, as well as the greater industry in general. Not surprisingly I was incredibly impressed by the astute questions received and have attempted to respond to as many as possible in a consolidated manner. We understand fully our responsibility to try to maximize shareholder value and make all of our decisions based on that first and foremost. We believe the days, weeks and months ahead will prove to be exciting for everyone, as we continue to make 2016 a truly exceptional year.

Shane O'Driscoll.

Can you elaborate on what's been happening in the past year?

Over the past year we scaled back on marketing dollars and focused on securing the best platform for the next phase of our growth. Our acquisition took several months from start to closing and we also focused our energies on bringing all of the US Financial filings up to date.

Other than Apollo, are there any more convertible notes left?

Technically our initial funders and long-term investors can convert a portion of their debts into equity but have chosen not to in the past two years. RDRD's debt, for example, has been on the company's books since then. Apollo acquired ALL of the other convertible notes since then with the exception of one 40k note. All of our outstanding notes are fully disclosed in our 10-K and will be updated with each quarterly filing.

What's with the 6 million dollars of debt in the filings?

A substantially large portion of our debt and all of our residual preferred stock obligations predate the merger with SeanieMac International to the days when the public company was Compliance Systems. We believe many of these obligations can and will be settled or removed from the balance sheet in 2016.

Are there any other acquisitions in mind or on the horizon?

We are very actively seeking potential opportunities and partners, as well as financial support to pursue other acquisitions. We have reached out to various candidates and cannot divulge at the present time if any of these discussions will result in an actual transaction, but we think we offer a compelling value proposition to prospective candidates. With the right deals our goal of reaching 100 Million in revenue is attainable given the exponential growth the industry is seeing every year. We of course will keep you up to date as things progress.

Do you have any plans on a reverse merger?
No.

IMO, could be wrong, but this is closing on issues with convertible notes the past few months. They soon to be a thing of the past and huge revenues expected with two sites on a better and much more profitable betting site starting in about two weeks.

[PENNIEStoSTACKS]

BOTTOMS UP

[MaxPowerLove$Ihub]

***** $CHRO: L2 Screenshot: *****

[MaxPowerLove$Ihub]

$GNPT, $MEDT, $SDVI, COBI, $VGID, $SURE, $LUSI: The next $.00x stock!

[mrfence]

$MNGA~ Here comes da pinch, WHAT A GAS!

[Pennybuster]

$AMPE .947 Big Gap 2 Fill Here. OverSold. Chart Inside.

[Pennybuster]

$TRXC Battered BioTech Chart and News Inside.




TransEnterix, Inc. Announces First Sale of ALF-X? Surgical Robotic System

RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the first global sale of its ALF-X? Surgical Robotic System to Humanitas Hospital in Milan, Italy .

"We are pleased to announce the first global sale of our ALF-X System," said Todd M. Pope , President and CEO of TransEnterix . "Humanitas is an outstanding academic hospital with a respected multi-specialty surgical program. The ALF-X enables an enhanced surgical program through the use of advanced robotic technology with responsible procedural economics."

"The initiation of sales of ALF-X represents an important milestone towards realizing our vision to transform surgical robotics," continued Mr. Pope . "We have made substantial progress building out our global commercial, distribution and service capabilities throughout 2016."

The ALF-X System is CE Marked and is indicated for use in general surgery, gynecology, urology and thoracic surgery. We are actively preparing a submission for U.S. FDA Clearance for the ALF-X System.

About Humanitas

Humanitas is a highly specialized research and teaching hospital partnered with Humanitas University Medical School . Humanitas University trains globally-oriented healthcare professionals through state-of-the-art interactive teaching methods and close integration with their clinical and research community. Humanitas believes that it is essential to unite organizational efficiency and clinical quality. For this reason, it was the first Italian general hospital and one of the few in Europe , to be certified for quality by the International Joint Commission .

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the ALF-X Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The ALF-X Surgical System has been granted a CE Mark but is not available for sale in the US. For more information, visit the TransEnterix website at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating the ALF-X® System and SurgiBot™ System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 , our other filings we make with the SEC . You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.



View source version on businesswire.com: http://www.businesswire.com/news/home/20160801006226/en/

For TransEnterix, Inc.
Investor Contact:
Mark Klausner , 443-213-0501
[e-mail]
or
Media Contact:
Mohan Nathan , 919-765-8400
[e-mail]

Source: TransEnterix, Inc.

[Pennybuster]

$YECO 1.59 Chart.

[Pennybuster]

$RNVA .485 14.8M O/S 4.4M Float. At Bottom. DD Inside.

Overview

We are a vertically integrated public healthcare holding company. We focus on serving essential healthcare categories, especially those with unmet needs and significant opportunities for innovation-driven solutions.
We develop and operate forward-thinking businesses, systems and services to support better treatment outcomes, more cost-effective patient care, and optimized revenue streams. We are committed to providing unmatched service excellence across our entire suite of solutions while building on the best medical science and innovative technologies available. We also maintain the highest standards of corporate transparency, fiduciary responsibility, accountability, and regulatory compliance.

http://ir.rennovahealth.com/

http://www.rennovahealth.com/

[mrbizzard]

IDDR potential bouncer

[BottomBounce]

$AMRS Amyris is industrializing synthetic biology to produce target molecules for our partners and customers around the globe.

Our industrial production relies on established fermentation processes that use our proprietary yeast strains to convert the sugar source into target molecules such as Biofene. While we can use any fermentable sugar in our process, we are focused on Brazilian sugarcane because of cost, availability, and the local industry’s ability to meet international sustainability standards.

Amyris employs a multi-stage scale-up approach to progress from laboratory scale to commercial production scale. We maintain a constant feedback loop between our laboratory, where strains are initially created and improved, and our two pilot plants, where we expose those strains to conditions that simulate an industrial production environment. This allows us to focus our microbe development resources on those strains that demonstrate the potential to scale effectively.

Once a microorganism has been engineered in our laboratories and a scale-up production process tested in our pilot and demonstration plants, Amyris begins commercial production at industrial scale. To support our initial commercial production, Amyris leveraged contract-manufacturing capabilities until it completed construction and commissioning of its own production facility.

Our first purpose-designed industrial manufacturing production facility began operations in Brazil in December 2012. Located adjacent to the Tonon Paraíso mill, we convert sugarcane syrup into farnesene and other tailored molecules for a range of renewable products for our customers. Amyris has plans for additional production facilities to meet growing demand for its renewable products.

https://amyris.com/innovation/industrial-production/

[Pennybuster]

$COYN 1.30 Bounce Off 52 Wk Low. O/S 8.80M


Float 6.70M


Insiders 42.96%



http://www.copsync.com/

[MaxPowerLove$Ihub]

****** $$$$$ $CHRO: $.05s+ soon $$$$$ *****

[MaxPowerLove$Ihub]

$CHRO: $.048s...& achieving .05s marks our first milestone to the path of $.25s+!


- Go CHRO

[MaxPowerLove$Ihub]

$CHRO: Most of the time, experiencing pure ask spanking vol

[mrbizzard]

SMCE oversold possible 200 bounce coming

[Pennybuster]

$SKLN .119 52 Week Low Chart.

[Pennybuster]

$TBIO Transgenomic Study Data Shows 100% Concordance between ICE COLD-PCR™ (ICP) Liquid Biopsies & Conventional Tissue Biopsy Res...




Transgenomic, Inc. NASDAQ:$TBIO

Today : Monday 16 May 2016


ICE COLD-PCR-Enriched Results Identify All Mutations Detected by Standard Tissue Biopsy PCR; ICP Also Identified Additional Mutations Missed by Conventional Tissue Biopsy

Study Confirms ICE COLD-PCR’s High Sensitivity, Which Enables Use of Plasma-based Liquid Biopsies for Cancer Mutation Detection and Monitoring

Transgenomic, Inc. (NASDAQ:TBIO), today announced new concordance study data confirming the superior performance of its ICE COLD-PCR™ (ICP) enrichment technology over standard biopsied tissue PCR results for detection of tumor mutations in cancer patients. The data show that plasma-based liquid biopsy testing using ICP is 100% concordant with an established approach that uses standard PCR. The matched patient data further indicate that the ICP-enabled liquid biopsies detected more tumor mutations than tissue biopsy testing using standard PCR. Transgenomic is in the process of submitting the study to a peer-reviewed scientific publication.

The concordance study was reviewed by Anil Vachani, MD, MS, Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and a Director of Clinical Research at the University of Pennsylvania Perelman School of Medicine. Dr. Vachani’s research includes the study of methods to optimize the use of targeted cancer therapies. Dr. Vachani noted, “High sensitivity detection of genetic biomarkers from cell free DNA has the potential to provide guidance to clinical oncologists for personalized, precision cancer treatment. Liquid biopsies are a source of genetic information when there is no available tumor tissue and they make it possible to monitor treatment effectiveness and the emergence of drug resistance on an ongoing basis, thereby enabling more effective real-time treatment decisions. This can be critical for patients with metastatic disease. Based on these initial encouraging results, ICP may be a useful technology for helping to facilitate the broad use of cell free DNA liquid biopsies in cancer. I look forward to seeing the results of further confirmatory studies now underway.”

In this study, Transgenomic analyzed 22 matched samples from chemo-naïve late-stage colorectal cancer (CRC) patients. The purpose was to compare the concordance between tissue biopsy results using traditional PCR and Sanger sequencing with plasma liquid biopsy results obtained using ICE COLD-PCR and Sanger sequencing. The study also compared mutation detection results from the matched tissue/FFPE samples analyzed with Sanger sequencing and either standard PCR or ICE COLD-PCR.

The concordance between the conventional tumor biopsy results and the matched ICP-enriched plasma sample liquid biopsy results was 100%. In addition, the ICP-enriched biopsies identified seven mutations missed by the conventional PCR approach--four additional mutations were identified in the ICP-enriched plasma samples and three additional mutations were identified in tissue samples that were analyzed with ICE COLD-PCR.

Transgenomic President and CEO Paul Kinnon commented, “We are delighted with the latest results from our studies, which show 100% concordance between ICE COLD-PCR-based liquid biopsy results and tissue-based results from the same patients, as well as ICP’s superior performance in identifying tumor mutations that were missed by conventional PCR methods. This new data further validates the clinical utility of ICP as a robust method to detect and monitor actionable mutations from a liquid biopsy sample, an essential component needed for adoption of precision medicine. We expect to submit additional data to peer reviewed scientific settings in the coming months.”

Transgenomic’s ICP cancer assays exponentially amplify targeted regions of exons that have been determined to be predictive and/or prognostic for many types of cancer, including colorectal cancer, melanoma, breast cancer and non-small cell lung cancer. The 17-target mutation panel matches the set of mutation data currently used routinely in clinical settings for identifying and selecting therapeutic or clinical trial options for patients being treated for multiple cancer types. Additional mutations are being added as the science advances.

ICE COLD-PCR achieves its ultra-high sensitivity through selective amplification of mutant DNA. The result is up to a 500-fold increase in sensitivity in identifying mutations with the most precise sequence alteration detection rates available. ICP was originally developed by the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute, which has exclusively licensed rights to the technology to Transgenomic.

For more information about Transgenomic’s cancer assays, click here.

About Transgenomic
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR™. Transgenomic also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission, including in Transgenomic’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 14, 2016. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.



View source version on businesswire.com: http://www.businesswire.com/news/home/20160516005244/en/

Media:
BLL Partners LLC
Barbara Lindheim, 212-584-2276
[e-mail]
or
Investors:
Transgenomic Investor Relations
[e-mail]

[MaxPowerLove$Ihub]

$MFST: MEDIFIRST SOLUTIONS ANNOUNCES TIME MACHINE LASER SERIES UPDATE
Date : 04/05/2016 @ 11:00AM
Source : InvestorsHub NewsWire
Stock : Medifirst Solutions Inc. (QB) (MFST)

Freehold, NJ -- April 5, 2016 -- InvestorsHub NewsWire -- MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “company” or “Medifirst”) would like to continue to update shareholders on recent developments regarding its FDA 510(k) submission for The Time Machine Laser Series.

Medifirst is pleased to announce that its The Time Machine Laser Series engineers have upgraded the lasers and made them more durable in addition to successfully making several internal modifications as requested as part of the FDA review process. The Company has upgraded its laser device with new components including an improved LCD screen that makes the device not only more durable but easier to repair in the unlikely case of an accident. Additionally, these upgrades can help expedite repairs and possibly avoid extensive delays that could involve the lasers having to be shipped back to the manufacturer.

The Company is also pleased to announce that the Time Machine Laser has successfully passed five laboratory tests as required by the FDA as part of the EMC evaluation currently being conducted and the team continues to work diligently to complete the testing process. Commented CEO Bruce J. Schoengood, “We continue to work with our team to expeditiously respond to all requests towards completion of the testing phase as part of the FDA review process. Working with our experienced team of laser engineers, our goal is to provide hospitals, surgical centers and healthcare professionals with our Laser Series that meets all FDA standards as required for a hand-held laser device.”

Regarding International sales, the Company has preformed several demonstrations and have received very strong interest from distributors in the UK, Australia, Russia and Brazil. The Company is currently preparing to initiate a national and international sales strategy upon successfully getting the 510(k) clearance from the FDA.


About Medifirst Solutions, Inc.
Medifirst Solutions, Inc. is a Nevada corporation that is headquartered in New Jersey. The company seeks innovative medical and healthcare products and technologies which are targeted to both medical and healthcare professionals, as well as everyday consumers. Medifirst is developing and establishing both consumer and professional medical cliental that can serve as a pipeline that will allow for distribution of future products and services. For more details visit www.medifirstsolutions.com for more information.

About the Lasers
Medical Lasers Manufacturer, Inc., a Nevada company, (“MLM”), a Medifirst subsidiary, will specialize in producing high quality diode-pumped solid-state lasers. The laser division, including products and treatment programs, will be operated out of MLM. The company’s focus is to help patients with specific cosmetic skin conditions, as well as relief of muscle and joint pain and muscle spasm and inflammation. Driven by the huge demand for minimally invasive skin and pain treatments, the global market for medical and therapeutic lasers have been estimated to grow as high as to $4 billion in 2015.


Forward-Looking Statements: The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements.


Contact: Investor Relations
Phone: [phone]
Email: [e-mail]
Website: www.medifirstsolutions.com



- Go MFST

[Pennybuster]

$LIFE 2.83 52 Week Low Cash Per Share 4.04
Bunch Of Insider Buying in the $3's
Oversold
http://www.finviz.com/quote.ashx?t=LIFE …

[MaxPowerLove$Ihub]

$CHRO: Generally, humping the ask...non-stop~ like a horny-teenager or confused young-man humping Justin Justin Bieber

- Go CHRO

[Pennybuster]

$TBIO .51 x .53 Bottom Biotech DD Inside.










Stock Price History
Beta: 0.22
52-Week Change3: -67.53%
S&P500 52-Week Change3: -2.29%
52-Week High (May 29, 2015)3: 3.75
52-Week Low (Feb 23, 2016)3: 0.49
50-Day Moving Average3: 0.62
200-Day Moving Average3: 0.79
Share Statistics
Avg Vol (3 month)3: 126,551
Avg Vol (10 day)3: 85,925
Shares Outstanding5: 20.70M
Float: 8.41M
% Held by Insiders1: 18.61%
% Held by Institutions1: 12.60%
Shares Short (as of Apr 15, 2016)3: 377.32K
Short Ratio (as of Apr 15, 2016)3: 1.92
Short % of Float (as of Apr 15, 2016)3: 3.31%
Shares Short (prior month)3: 435.66K









https://finance.yahoo.com/q/ks?s=TBIO+Key+Statistics




Major Holders: https://finance.yahoo.com/q/mh?s=TBIO+Major+Holders



Profile



Transgenomic Inc.
12325 Emmet Street
Omaha, NE 68164
United States - Map
Phone: [phone]
Fax: [phone]
Website: http://www.transgenomic.com




Details
Index Membership: N/A
Sector: Technology
Industry: Scientific & Technical Instruments
Full Time Employees: 150






Business Summary
Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies, and clinical and research services primarily in the United States. The company provides genetic analytical laboratory services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. It employs various genomic testing service technologies, including ICE COLD-PCR, a proprietary platform technology that enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA, and circulating tumor cells. The company was founded in 1997 and is headquartered in Omaha, Nebraska.




https://finance.yahoo.com/q/pr?s=TBIO+Profile





Chart: http://stockcharts.com/h-sc/ui?s=tbio

[MaxPowerLove$Ihub]

$CHRO is hotter than any California gurls!

According to Lady Gaga, Miley Cyrus...She's, definitely, hotter than Katy Perry!

- Go $CHRO

[MaxPowerLove$Ihub]

***** $CHRO: Touched $.05s...a new beginning! $tarting to $short $queeze Motherflower Trolls n Dirty-Leprechauns *****

[MaxPowerLove$Ihub]

$MEDT, $COBI, $SURE: Getting closer to $.00x